Branch Retinal Vein Occlusion (BRVO)

The most common symptom of BRVO is a painless decrease in vision, usually in one eye. If the blocked vein drains the area near the macula, you may notice blurred central vision, difficulty reading, or distortion where straight lines appear wavy. Some patients describe a dark or shadowy area in part of their visual field corresponding to the section of retina affected by the occlusion.

Retinal hemorrhages associated with BRVO can cause new floaters, which are small spots or strands that drift across your vision. If the bleeding is extensive, you may notice a larger area of dimness or a curtain-like shadow in your peripheral vision. These symptoms may develop suddenly over hours or progress gradually over several days.

In some cases, BRVO affects a small area of the retina away from the macula, and you may not notice any change in vision at all. These cases are sometimes discovered incidentally during a routine dilated eye exam. Even when symptoms seem minor, prompt evaluation is important because complications such as macular edema can develop over time.

The primary treatment for BRVO-related macular edema is anti-VEGF injection therapy, which involves placing medication directly into the eye to reduce swelling and leakage from damaged blood vessels. Commonly used medications include ranibizumab (Lucentis), aflibercept (Eylea), and bevacizumab (Avastin). Some patients may also benefit from intravitreal steroid injections if they do not respond adequately to anti-VEGF therapy. Retinal laser photocoagulation may be recommended for patients who develop neovascularization or in specific clinical situations where laser can help prevent further complications.

BRVO can cause lasting vision changes, particularly when macular edema is present for an extended period before treatment begins. Chronic swelling can damage the photoreceptor cells in the macula, leading to irreversible central vision loss. However, many patients experience meaningful improvement with prompt anti-VEGF treatment, and some recover a significant portion of their lost vision. The key factor influencing outcomes is how quickly treatment is started after symptoms appear.

BRVO is most common in adults over 50, and the risk increases with age. People with high blood pressure, diabetes, high cholesterol, or a history of cardiovascular disease are at significantly higher risk. Smoking and obesity also increase susceptibility. In younger patients, blood clotting disorders or inflammatory conditions should be considered and evaluated.

The visual prognosis for BRVO varies considerably. Approximately one-third of patients improve spontaneously without treatment, one-third remain stable, and one-third experience worsening vision without intervention. With modern anti-VEGF therapy, the majority of treated patients achieve stable or improved vision. Long-term management typically involves regular monitoring with OCT imaging and additional injections as needed, sometimes over months or years.

The most effective prevention strategy is managing the cardiovascular risk factors that contribute to vein occlusion. Keeping blood pressure well controlled is especially important, as is managing diabetes and cholesterol through medication, diet, and regular exercise. Quitting smoking significantly lowers vascular risk. Regular follow-up with both your eye doctor and primary care physician helps ensure that systemic conditions are being treated appropriately.

You should seek prompt evaluation if you notice any sudden or unexplained change in your vision, including blurriness, distortion, new floaters, or a shadow in any part of your visual field. These symptoms can indicate BRVO or other serious retinal conditions such as retinal artery occlusion or retinal hemorrhage. Early diagnosis gives you the best chance of preserving your vision and preventing complications.